Repros in the News

All Releases

View Summary Repros Submits New Drug Application to FDA for Androxal (R)

Feb 2, 2015

PDF 63.0 KB Add to Briefcase
View Summary Repros Initiates Two Phase 2B Uterine Fibroid Studies

Dec 29, 2014

PDF 21.0 KB Add to Briefcase
View Summary Repros Updates Androxal(R) Global Regulatory Status

Dec 29, 2014

PDF 20.9 KB Add to Briefcase
View Summary Court Rules Inventors Correctly Named on Androxal(R) Patents

Dec 29, 2014

PDF 20.6 KB Add to Briefcase
View Summary Repros Therapeutics Inc.(R) Reports Third Quarter 2014 Financial Results

Nov 10, 2014

PDF 26.2 KB Add to Briefcase
View Summary Repros Holds Constructive Meeting With FDA Regarding Androxal(R) NDA Filing

Nov 6, 2014

PDF 21.0 KB Add to Briefcase
View Summary Repros to Webcast Investor and Analyst Day on October 31st

Oct 27, 2014

PDF 22.0 KB Add to Briefcase
View Summary Results From Long-Term Study of Androxal(R) Exhibit Positive Safety Profile

Oct 21, 2014

PDF 26.6 KB Add to Briefcase
View Summary Upcoming FDA Meeting to be Type C Meeting

Oct 16, 2014

PDF 19.5 KB Add to Briefcase
View Summary FDA Schedules Type B Pre-NDA Meeting With Repros

Sep 26, 2014

PDF 19.8 KB Add to Briefcase
View Summary Androxal(R) Second Pivotal Study Achieves Superiority in Top Line Analysis for Both Co-Primary Endpoints Versus Marketed Topical Gel in the Treatment of Secondary Hypogonadism

Sep 25, 2014

PDF 76.1 KB Add to Briefcase
View Summary Repros Gives Update on Androxal(R) With Respect to Recent FDA Advisory Panel Outcome and Announces Upcoming Presentation at Biocentury

Sep 22, 2014

PDF 24.8 KB Add to Briefcase
View Summary Androxal(R) Achieves Superiority in Top Line Analysis for Both Co-Primary Endpoints and Various Secondary Endpoints Versus Marketed Topical Gel in First of Two Identical Studies in the Treatment of Secondary Hypogonadism

Aug 27, 2014

PDF 81.9 KB Add to Briefcase
View Summary Repros Therapeutics Inc.(R) Reports Second Quarter 2014 Financial Results

Aug 11, 2014

PDF 25.8 KB Add to Briefcase
View Summary FDA Confirms Sperm and Testosterone Endpoints as Key Parameters for Assessment of Androxal(R) Versus Approved Topical Gel and Placebo

Jul 16, 2014

PDF 68.2 KB Add to Briefcase
View Summary Repros Fully Enrolls Second Previously Announced Head to Head Study of Androxal(R) Versus the Leading Topical Testosterone Gel

May 13, 2014

PDF 67.1 KB Add to Briefcase
View Summary Repros Therapeutics Inc.(R) Reports First Quarter 2014 Financial Results

May 12, 2014

PDF 23.9 KB Add to Briefcase
View Summary FDA Recommends Sperm Endpoints as Key Parameters for Assessment of Androxal(R) Versus Approved Topical Gel

Apr 30, 2014

PDF 68.3 KB Add to Briefcase
View Summary Repros Fully Enrolls First of Two Previously Announced Head to Head Studies of Androxal(R) Versus the Leading Topical Testosterone Gel

Apr 14, 2014

PDF 67.3 KB Add to Briefcase
View Summary Repros Allowed to Conduct Phase 1 and 2 Clinical Studies of Low Dose Oral Proellex(R) in the Treatment of Uterine Fibroids and Endometriosis

Mar 17, 2014

PDF 19.7 KB Add to Briefcase
Showing 41-60 of 190 Page: 1 2 3 4 5 6 7 ... 10  Previous 20 | Next 20
Add to Briefcase = add release to Briefcase
2408 Timberloch Place, B-7
The Woodlands, Texas 77380
281-719-3400
281-719-3446 fax